Evidence map›Paper›PMID 42403079›Full record

ReviewThe European journal of neuroscience2026

Freezing of Gait Levodopa Response Pattern in Parkinson's Disease Provides Clues to Pathophysiology.

Stewart A Factor, David Weinshenker, Jeanne Powell, Andrew S Monaghan, Daniel S Peterson, J Lucas Mckay

Abstract readReview
In one paragraph

Review in The European journal of neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Stewart A FactorJean & Paul Amos Parkinson's Disease & Movement Disorders Program, Department of Neurology, Emory University, Atlanta, Georgia, USA.ORCID 0000-0002-0449-973X
David WeinshenkerDepartment of Human Genetics, Emory University, Atlanta, Georgia, USA.
Jeanne PowellDepartment of Biomedical Informatics, Emory University, Atlanta, Georgia, USA.
Andrew S MonaghanSchool of Psychology, Queen's University Belfast, Belfast, UK.
Daniel S PetersonCollege of Health Solutions, Arizona State University, Phoenix, Arizona, USA.ORCID 0000-0002-4639-6544
J Lucas MckayJean & Paul Amos Parkinson's Disease & Movement Disorders Program, Department of Neurology, Emory University, Atlanta, Georgia, USA.

Funding

CS FoundationMiracle for Mom FoundationNIH HHS 1R01AG086533Parkinson's FoundationThe Curtis Family FundThe McCamish Parkinson's Disease Innovation Program at Georgia Institute of TechnologyThe Sartain Lanier Family Foundation
6 · The paper itself

Abstract

Freezing of gait (FOG) is a common and enigmatic feature of Parkinson's disease (PD) because of its episodic and unpredictable nature. It is now clear that FOG is not a monolithic phenomenon but instead exhibits substantial heterogeneity across patients, suggesting the existence of subtypes. Among the heterogeneous features are levodopa response patterns and nonmotor features, cognitive impairment and anxiety/depression. It remains an open question as to whether these phenotypes are the result of different pathophysiology. In this paper, we develop the hypothesis that levodopa response patterns may identify FOG subpopulations tied to nonmotor symptoms and alterations in different neurotransmitter systems. Here, we review the levodopa response patterns of FOG seen in PD based on a rigorous levodopa challenge paradigm using a 40% higher dose of levodopa and blood levodopa levels to demonstrate that the majority of patients are either levodopa responsive (OFF-FOG) or unresponsive (ONOFF-FOG). The literature demonstrates that executive and affective changes are not universal in FOG and actually relate closely to levodopa response patterns, OFF-FOG is associated with affective disorders, and ONOFF-FOG is related to cognitive decline. In turn, OFF-FOG and affective disorders appear to be associated with brain noradrenergic degeneration, whereas ONOFF-FOG and cognitive decline are associated with cholinergic loss. These observations suggest different therapeutic targets by subtype. We suggest that levodopa challenge testing may help stratify FOG patients in trials and mechanistic studies.

Indexed as

Antiparkinson AgentsGait Disorders, NeurologicLevodopaParkinson DiseaseAnimalsHumansAntiparkinson AgentsLevodopaanxietycholinergiccognitive impairmentdepressionnoradrenergicParkinson's disease

Identifiers

PMID42403079
PMCPMC13334237

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.